1. APDN's clinical lab submitted an LDT approval request for H5 bird flu test. 2. The AIH5 Dx assay aims to improve detection of H5N1 avian influenza.
The approval of AIH5 Dx could enhance APDN's market position and revenue. Historical data shows diagnostics' market growth during health crises boosts stock value.
The submission for an LDT involves significant potential for revenue and competitiveness in healthcare diagnostics. The urgency and public health relevance of influenza diagnostics enhance its importance.
Regulatory approvals typically lead to stock price increases shortly after announcement. Positive market response may occur if NYSDOH approval is granted swiftly.